FIELD: imaging and endoradiotherapy of diseases.
SUBSTANCE: invention is related to diseases in which prostate specific membrane antigen (PSMA) is involved. Compounds that bind or inhibit PSMA and, in addition, have at least one fragment capable of labelling with radioactive labels, are presented. Medical applications of such compounds are also presented.
EFFECT: imaging and endoradiotherapy inventions are proposed.
13 cl, 6 dwg, 10 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
NEW PSA-BINDING AGENTS AND THEIR USE | 2018 |
|
RU2787105C2 |
INHIBITORS OF VIIA FACTOR | 1999 |
|
RU2223967C2 |
RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS AND THEIR USE | 2018 |
|
RU2804297C2 |
PSMA-TARGET COMPOUND AND ITS COMPLEX WITH RADIONUCLIDES FOR THERANOSTICS OF TUMOR EXPRESSING PSMA | 2022 |
|
RU2803734C1 |
LIGANDS FOR MELANOCORTIN RECEPTORS | 2001 |
|
RU2246501C2 |
SYNTHETIC PEPTIDES REDUCING OR ELIMINATING BAGGY LOWER EYELIDS, AND APPLICATION THEREOF IN COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS | 2005 |
|
RU2387666C2 |
SOMATOSTATIN ANTAGONISTS | 2002 |
|
RU2263678C2 |
OXYTOCIN ANALOGUES | 2009 |
|
RU2496788C2 |
NOVEL METHODS OF PRODUCING BARUSIBAN AND INTERMEDIATE COMPOUNDS THEREOF | 2016 |
|
RU2726414C2 |
SOMATOSTATIN ANTAGONISTS | 2002 |
|
RU2328504C2 |
Authors
Dates
2023-11-09—Published
2018-12-11—Filed